GX G8
Alternative Names: GX-G8; Long acting glucagon like peptide 2 - GenexineLatest Information Update: 28 Jun 2023
At a glance
- Originator Genexine
- Class Antidiarrhoeals; Glucagon-like peptides; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Short bowel syndrome
- Discontinued Diarrhoea
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Short-bowel-syndrome in Europe (Parenteral)
- 19 May 2020 Discontinued - Preclinical for Diarrhoea (Chemotherapy-induced) in South Korea (Parenteral) (Genexine pipeline, May 2020)
- 19 May 2020 Phase-I clinical trials in Short bowel syndrome in Europe (Parenteral) (Genexine pipeline, May 2020)